Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Response to Irreversible Electroporation (NanoKnife ®) and a Checkpoint Inhibitor With or Without CpG Oligodeoxynucleotides for the Treatment of Stage IV Colorectal Cancer

NCT06047015 is registered in ClinicalTrials.gov with University of Saskatchewan as lead sponsor.

NCT NCT06047015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06047015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Response to Irreversible Electroporation (NanoKnife ®) and a Checkpoint Inhibitor With or Without CpG Oligodeoxynucleotides for the Treatment of Stage IV Colorectal Cancer
Lead sponsor
University of Saskatchewan
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
December 31, 2028
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastasis colon cancer